InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2024-09-05 00:00:00 ET · period of report 2024-09-03 · accession 0001968202-24-000125 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-09-05 2024-09-03 REGN McCourt Marion EVP Commercial S - Sale+OE $1,178.73 -1,000 12.9K -7% -$1.18M
D 2024-09-05 2024-09-03 REGN McCourt Marion EVP Commercial M - OptEx $381.40 +1,000 13.9K +8% +$381.4K
D 2024-09-05 2024-09-03 REGN McCourt Marion EVP Commercial M - OptEx $0.00 -1,000 8,000 -11% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-09-03 S D 1,000 $1,178.73 12,931 D — —
2 Common Common Stock 2024-09-03 M A 1,000 $381.40 13,931 D — —
3 Derivative Non-Qualified Stock Option (right to buy) 2024-09-03 M D 1,000 $0.00 8,000 D $381.40 · — to 2028-12-12 1,000 Common Stock (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.